SOLICITATION NOTICE
66 -- Upgrade BioVeris M-Series Analyzer
- Notice Date
- 7/6/2007
- Notice Type
- Solicitation Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70080-NG
- Response Due
- 7/17/2007
- Archive Date
- 8/1/2007
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Molecular Pharmacology (LMP) plans to procure on a sole source basis; one Upgrade-BioVeris M-Series Analyzer with BioVeris, Inc.; 16020 Industrial Drive, Gaithersburg, Maryland 20877. The LMP will be trading in this BioVeris M8 Analyzer which it acquired in 2004 and no longer meets its needs. This acquisition will be processed under FAR Part 12: Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-(b) (1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. The salient characteristics apply to the Upgrade-BioVeris M-Series Analyzer: Dimensions & Weight: W 14.8inches x H 11.7inches x D 14.8feet, Weight 35lbs. - electrochemiluminescent technology (BioVeris (BV) detection technology); - combination of sensitivity, reliability, speed, and flexibility; - platform for biological measurements; - electrochemiluminescent compounds (which include; the BV-TAG detection reagents); - compatible with the BV detection technology; - touch screen laptop computer with research software installed running on Windows operating system; - software shall provide a wide dynamic range of detection, up to 5 logs of electrochemiluminescence signal; - allow user-defined protocols and quality control tests; - track reagent use through sensors and store all results with a security encryption feature; - dispense reagents into sample wells of a 96-well plate; - interface with a robotic system; - integrated plate shaking system; - built-in barcode reader and will allow the sample results plus barcode information to be exported in standard ASCII format for an easy importation into other external programs for data analysis and manipulation; open transport case for increased mobility. Facts and Reasons to Justify Other than Full and Open Competition: 1. Statutory authority: Statute: 13.106-1(b) (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). Benefit: The purchase of an upgraded instrument, M1MR M-Series Analyzer, will allow the NCI to continue screening efforts to discover novel inhibitors of Tdp1 and HIV-1 integrase. Several small molecule chemical libraries are currently waiting to be screened. The acquisition of this instrument will promote translational development of novel anticancer and antiviral agents at NCI. 2. Justification: The NCI currently owns a M8 M-Series Analyzer from BioVeris that will be traded in for an advanced instrument, M1MR Analyzer. BioVeris develops biological detection systems based on its proprietary electrochemiluminescent technology (BioVeris (BV) detection technology), which provides a unique combination of sensitivity, reliability, speed, and flexibility. The M1MR Analyzer uses the BV? technology and provides a novel platform for biological measurements. Additionally, BioVeris has developed an assay specific for measuring inhibition of HIV-1 integrase using this method. This is the only known commercially available instrument supporting a medium- or high-throughput integrase assay utilizing the patented BVTM Technology. BioVeris incorporates its BV detection technology into its instrument systems, tests and reagents, which are the biological and chemical components used to perform such tests. BioVeris Corporation's worldwide patent portfolio broadly covers the use of BV technology in diagnostic and other biological applications and includes a number of issued patents covering electrochemiluminescent compounds. This includes BV-TAG detection reagents, compositions containing such compounds, the methods of making and using these compounds; and, BV detection technology systems adapted to detect and measure the compounds. The NCI requires the components of this instrument to be compatible with the BV detection technology. The Analyzer will include a touch screen laptop computer with research software installed running on Windows operating system. This software shall provide a wide dynamic range of detection, up to 5 logs of electrochemiluminescence signal. It will allow the use of user-defined protocols and will perform all quality control tests. It will track the reagent use through sensors and store all results with a security encryption feature. The system will have the ability to dispense reagents into sample wells of a 96-well plate. It will have the ability to interface with a robotic system and will offer an integrated plate shaking system. The analyzer will have a built-in barcode reader and will allow the sample results plus barcode information to be exported in standard ASCII format for an easy importation into other external programs for data analysis and manipulation. In addition, the system will have to be usable in open transport case for increased mobility. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM ET on July 17, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Malinda Holdcraft, Contract Specialist at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-70080-NG on all correspondence.
- Record
- SN01335775-W 20070708/070706220308 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |